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Abstract
We investigated the rates of the use of steroids in Japanese central serous chorioretinopa-
thy (CSC) cases and differences in the characteristics of CSC with and without steroids. A
total of 538 eyes of 477 patients diagnosed with CSC, with 3 months or more of follow-up
between April 2013 and June 2017 at 8 institutions. Patients with CSC with more than 3
months of follow-up were identified by OCT and fluorescein angiography at 8 institutions.
Data collected included patient demographics, history of corticosteroid medication and
smoking, spherical errors, findings of angiography, subfoveal choroidal thickness, and
changes through the follow-up period. Differences in these findings were analyzed in cases
with and without corticosteroid treatment. Among the 477 patients (344 men,133 women),
74 (15.5%) (39 men, 35 women) underwent current or prior steroid treatment. Cases with
steroids were higher age (p = 0.0403) and showed no male prevalence, more bilateral
involvement (p < 0.0001), and the affected eyes had multiple pigment epithelial detachment
(p <0.0001), more fluorescein leakage sites (p < 0.0001), greater choroidal thickness (p =
0.0287) and a higher recurrence rate (p = 0.0412). Steroids can cause severer CSC through
an effect on choroidal vessels and an impairment of retinal pigment epithelium.
Introduction
Central serous chorioretinopathy (CSC) is a disease in which serous retinal detachment is
seen, often associated with detachment of the retinal pigment epithelium (RPE) [1–10]. Fluo-
rescein angiography (FA) in eyes with CSC reveals one or more leakages through RPE defects,
and indocyanine green angiography (ICGA) often shows choroidal vascular hyperpermeability
[8,9]. Increases in the permeability of the choroidal vessels result in pigment epithelial detach-
ment (PED) and exudation of fluid into the subretinal space. It typically affects young and
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middle-aged adults, with men affected more commonly than women. Traditionally, CSC has
been found to be associated with psychological stress and type-A personality, but its pathogen-
esis remains unclear [10].
An association with corticosteroids had been postulated, and since Wakakura and Ishikawa
[11] demonstrated 5 cases showing worsening of CSC during corticosteroid therapy in the Jap-
anese-language literature in 1980, more attention has been paid to the risk of steroids with
respect to CSC. Not only systemic administration but the local routes of steroids can cause
CSC [12–22].
A history of CSC can increase the risk of neovascular age-related macular degeneration
(AMD), especially polypoidal choroidal vasculopathy, and recent studies indicate a common
feature of thick choroid among these diseases [23–25]. Hence it is desirable to learn more
about CSC pathogenesis, including the possible risks of steroids.
In this study, we investigated the rates of the use of steroids in Japanese CSC cases and dif-
ferences in the characteristics of CSC with and without steroids. In addition, choroidal thick-
ness was compared among patients.
Participants and methods
This was a multicenter retrospective study (participating facilities: Hyogo College of Medicine,
Sumitomo Hospital, Tokushima University, Mie University Graduate School of Medicine,
Sapporo City General Hospital, Nara Medical University, Nagoya City University Graduate
School of Medical Sciences, and Fukui University). The study was approved by the ethics com-
mittees of all participating centers (ethics committee of the Hyogo College of Medicine, num-
ber 2387, Sumitomo Hospital, number 29–28, Tokushima University, number 2831, Mie
University Graduate School of Medicine, number 3151, Sapporo City General Hospital, num-
ber H29-054-364, Nara Medical University, number 1464, Nagoya City University Graduate
School of Medical Sciences, number 60160195, Fukui University, number 2017000). The need
for written informed consent was waived by the ethics committees due to a retrospective and
observational nature of the study. The data acquired in the course of the data analysis were
anonymized before we accessed them. The study complied with the Declaration of Helsinki.
In this study, patients who showed submacular fluid associated with CSC in at least one eye
and were followed for more than 3 months between April 2013 and September 2017 were
included. The diagnosis of CSC was based on ocular examination, a typical fluorescein leakage
seen in CSC and subretinal fluid on OCT. Eyes showing the occult type-leakage or irregular,
broad elevation of the RPE at the macula, those were indicative of CNV, were excluded.
Patients with other retinal and choroidal abnormalities showing intra- and subretinal hemor-
rhage were also excluded. Medical data on patients’ ages, gender, disease bilaterality, history of
steroids, smoking history, and history of medication by antianxiety drug, were collected. Fol-
lowing data were obtained from affected eyes and if both eyes had CSC, we chose one eye with
later onset or randomly; best corrected visual acuity, spherical equivalents, the numbers of
regions showing leakage on FA, the presence of choroidal vascular hyperpermeability on later-
phase ICGA, and subfoveal choroidal thickness were collected as possible. The reading of the
angiography was done at individual centers for the purposes of this study using the protocol
described. The subfoveal choroidal thickness was obtained from 426 eyes from the collected
images of the spectral-domain OCT of Spectralis (Heiderbelg Engineering, Heiderbelg, Ger-
many) or Cirrus (Carl Zeiss Meditec, Inc, Dubrin, CA). This was measured as the vertical dis-
tance between the outer border of the RPE and the chorioscleral border with duplicate
doctors. In this study, the values of choroidal thickness obtained by means of different
CSC with and without steroids
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instruments were used without adjustment because the error between different instruments
has been reported to be less than the inter-observer difference [26].
Major outcomes were the rate of patients who had undergone administration of steroids
before they were diagnosed with CSC and differences in characteristics as opposed to eyes
without steroid usage.
BCVA was examined using Landort C chart and then converted to logMAR (logarithm of
the minimum angle of resolution) for statistical analysis. Analysis was performed with JMP
software (Version pro 13, SAS, Cary, NC). To compare the two groups, Student’s t test and
Pearson’s chai-square test were performed as appropriate. Multivariate analysis was performed
to determine whether the use of steroids significantly affects choroidal thickness. Values are
shown as mean±standard deviation. The statistical significance of P values was set at 0.05 or
less.
Results
Patients’ demographics
We examined the records of 538 eyes from 477 patients (344 men and 133 women, M/F ratio
2.6:1) by CSC in 8 hospitals. The mean age was 53.7 ± 11.3 (range 29–89). Sixty-one patients
(12.8%) had bilateral disease. Answers about smoking history was obtained from 345 patients
and previous or current smoking was recorded for 147 patients (42.6%). Of those, 135 patients
(91.8%) were male. Ten patients took one or another anti-anxiety drug.
Corticosteroid medication
Seventy-four patients (15.5%; male 39, female 35) had current or prior systemic steroid histo-
ries. The number of current users was 49 and of prior users 14, but no information was avail-
able for 11 patients. The average periods of steroid use were 51.1 (range 1 to 120) months for
the current users and 20.5 (range 1 to 240) months for the prior users.
The major reasons for the use of steroids were systemic lupus erythematosus (12 patients),
nephropathy or post-renal transplantation (12 patients), and arthritis (10 patients). A local
ointment was prescribed for dermatitis in the case of one male patient. In the case of four
patients, systemic steroids were prescribed by an ophthalmologist: for recurrent scleritis in one
patient and CSC or chorioretinitis in three patients. Sixteen patients discontinued steroids
after the development of CSC.
Characteristics of affected eyes
The average spherical errors of the affected eyes were -0.61 ± 2.26 diopters (range: -9.0 to
+ 8.25). Thirty-nine eyes (8.18%) showed multiple PED. At least one region of fluorescein dye
leakage within the macula in 235 eyes and multiple fluorescein leakage sites were seen in 225
eyes. ICGA was available for 305 eyes, and 230 eyes (75.4%) showed choroidal vascular hyper-
permeability (CVH). Choroidal thickness was measured for 426 eyes, and the average thick-
ness was 375 ± 100 (range, 136–674) microns. Details were shown in S1 Dataset.
Differences in findings with and without corticosteroid medication
Differences in patient background are shown in Table 1. Cases with steroids showed older age
(p = 0.0403), no male prevalence, and more bilateral involvement (p < 0.0001). The number of
cases with smoking history was significantly low (p = 0.0345) and that with the history of anti-
anxiety drug was significantly high (p = 0.0016) in the group with steroids.
CSC with and without steroids
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A comparison of the characteristics of eyes with and without steroid usage is shown in
Table 2.
Choroidal thicknesses were available for 426 eyes from 426 patients, and 66 patients
(15.5%) had undergone steroid treatment. Of the 51 eyes for which choroidal thicknesses
were not available, 15.7% (8 eyes) received steroid treatment, and thus these two percentages
were almost the same. The choroids of the eyes that had received steroid treatment were
significantly thicker than those of the patients who had not undergone steroid treatment
(p = 0.0287). (Fig 1). The choroidal thickness was not significantly different between the cur-
rent (391.8 μm) and prior (415.5 μm) steroid users (p = 0.501).
Table 1. Differences in patients backgrounds.
Total Steroid (+) Steroid (-) P Value
No. of cases 477 74 403
Age (yrs)
Mean (SDa) 53.7 (11.3) 56.1 (11.8) 53.2 (11.2) 0.0403�
Gender (male/female) 344/133 39/35 305/98 <0.001†
Bilateral involvement (%) 61 (12.8) 31 (41.9) 30 (7.4) <0.0001†
Smoking (no. of cases/data available) (%) 147/345(42.6) 13/46 (28.3) 134/299 (44.8) 0.0345†
Antianxiety drug (no. of cases/data available) (%) 10/445(2.2) 5/66 (7.6) 5/379(1.3) 0.0016†
a SD = standard deviation
� Student’s t test
† Pearson’s chi-square test
https://doi.org/10.1371/journal.pone.0213110.t001
Table 2. Characteristics of eyes with and without steroid use.
Total Steroid (+) Steroid (-) P Value
No. of eyes (%) 477 (100) 74 (15.5) 403 (84.5)
Spherical equivalent (diopters)
Mean (SDa) -0.61 (2.26) -0.30 (1.70) -0.67 (2.34) 0.1920�
Best corrected visual acuity (logMARb)
Mean (SDa) 0.12 (0.24) 0.07 (0.25) 0.03 (0.19) 0.1950�
Multiple PEDc (%) 39 (8.18) 25 (33.8) 14 (3.5) < 0.0001†
Fluorescein angiography findings
Data available (n) (%) 464 70 (15.1) 394 (84.9)
leakage involving the fovea
(n) (%)
235 (50.7) 40 (57.1) 195 (49.5) 0.2373†
Multiple leakage sites (n) (%) 223 (48.3) 50 (71.4) 173 (44.1) < 0.0001†
Indocyanine green angiography findings
Data available (n) (%) 305 45 (14.8) 260 (85.3)
Choroidal vascular hyperpermeablitiy (n) (%) 230 (75.4) 38 (84.4) 192 (73.9) 0.1274†
Choroidal thickness (μm)
Data available (n)(%) 426 66 (15.5) 360 (84.5)
Mean (SDa) 375 (100) 399 (108) 370 (98) 0.0287�
a SD = standard deviation
b logMAR = logarithm of the minimum angle of resolution
c PED = pigment epithelial detachment
� Student’s t test
† Pearson’s chi-square test
https://doi.org/10.1371/journal.pone.0213110.t002
CSC with and without steroids
PLOS ONE | https://doi.org/10.1371/journal.pone.0213110 February 28, 2019 4 / 9
To identify the major factors associated with choroidal thickness, we performed multivari-
ate analysis among the factors of sex, age, steroid treatment, spherical errors, and the presence
of choroidal vascular hyperpermeability. The results showed that choroidal thickness was sig-
nificantly associated with younger age (p < 0.0001), more spherical equivalent (p< 0.0001),
the use of steroids (p = 0.0155), and males (p = 0.0482), that is, the steroids independently
increased choroidal thickness. No relationship was observed in the case of choroidal vascular
hyperpermeability (p = 0.6753).
Follow-up
The average follow-up period was 14.5 ±14.5 months (range, 3–144 months). During the fol-
low-up period, 366 eyes (76.7%) underwent treatment, including laser photocoagulation in
133 eyes, photodynamic therapy in 220 eyes, and intravitreal anti-VEGF drug injection in 24
eyes. In the cases with steroids, 52 eyes (70.3%) underwent treatment. Laser photocoagulation
was done for 29 eyes, photodynamic therapy for 26 eyes, and intravitreal anti-VEGF drug
injection for 2 eyes. In the cases without steroids, 314 eyes (77.9%) underwent treatment. Laser
photocoagulation was done for 104 eyes, photodynamic therapy for 194 eyes, and intravitreal
anti-VEGF drug injection for 22 eyes. Recurrences were recorded in 121 eyes (25.4%), and the
rate was significantly higher in eyes with steroids (35.1%) than without steroids (23.6%)
(p = 0.0356).
Discussion
This study included a relatively large number of Japanese patients with CSC, and analysis
focused on patient background with and without the use of corticosteroids. Many studies have
indicated an association of steroids with CSC. According to a recent systematic review analyz-
ing risk factors for CSC [27], the odds ratio (OR) for steroids was 4.29, and this number was
the highest among possible risk factors, including Helicobacter pylori infection (OR = 3.12),
autoimmune disease (OR = 3.44), psychopharmacologic medication use (OR = 2.69), and
type-A behavior (OR = 2.53).
Fig 1. Dot plot of choroidal thickness of eyes with and without steroid use. Legend: Choroid was significantly thick
in eyes with steroids.
https://doi.org/10.1371/journal.pone.0213110.g001
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The patients included in this study might have had severer CSC because they were referred
by primary clinics and were followed for more than 3 months in one or another of the various
hospitals. The average age of the patients was 53.7 years, higher than the 41 [28], 45 [29], and
51 [19] years in previous reports. The male / female ratio was 2.6, and the rate of cases with a
smoking history was 42.6%. According to a 2017 survey by Japan Tobacco, Inc. (website of the
Ministry of Health, Labor and Welfare in Japan, http://www.health-net.or.jp/tobacco/product/
pd090000.html), the average rate of smoking among Japanese was 18.2%, and for males aged
30–50, the rate was about 35%, therefore, CSC patients have higher rate of smoking habit.
The affected eyes were mostly emmetropic, although the myopic population is increasing in
Japan. More than half showed multiple leakage points on FA, and more than three-quarters
showed choroidal vascular hyperpermability on ICGA. The average choroidal thickness was
375 microns.
Use of corticosteroids was confirmed in 74 cases (15.5%), and the rate was high compared
with previous studies, for example, 3.3% [15], 9.1% [28], and 14.4% [29], possibly due to the
inclusion of severer cases. More than 60% of the patients were current users, and in 4 cases,
steroids were prescribed by ophthalmologists. Bilateral CSC tends to be misdiagnosed as chor-
ioretinitis or Harada disease, as previously reported [20]. The duration of steroid use was rela-
tively long.
In the comparison with and without steroids, several differences were identified. CSC
related to glucocorticoids showed lower male predominance, higher age, and more frequent
bilaterality at significant levels, as previously reported [22]. The rate of having a smoking his-
tory was significantly lower in cases with steroids, while it reached to 44.8% in cases without
steroids. Antianxiety drug was taken more frequently in cases with steroids.
On FA, CSC with steroids showed significantly more leakage sites, including the fovea and
multiple PEDs. ICGA had a greater tendency to show choroidal vascular hyperpermeablitiy,
and the choroid was significantly thicker in eyes with steroid treatment than in those without
treatment. The multivariate analysis showed that steroid treatment can increase choroidal
thickness independently of age, spherical errors, and gender [30, 31].
Choroidal vascular hyperpermeablitiy and increased choroidal thickness in eyes with CSC
indicate the involvement of choroid in pathogenesis [32,33], and our study indicates that ste-
roids can cause CSC via choroidal vascular changes. A previous pilot study evaluating the effect
of intravenous drip of steroids on choroidal thickness revealed that high-dose steroids did not
alter choroidal thickness, but one of 20 patient developed CSC with increased choroidal thick-
ness [34]. These results suggest that subjects who show susceptibility of steroids can develop
CSC with increased choroidal thickness. On the other hand, a recent study comparing choroi-
dal thickness in 25 eyes with CSC secondary to systemic corticosteroid use and with idiopathic
CSC showed that the mean central choroidal thickness in secondary CSC was significantly less
[35]. They also found a significantly smaller proportion of cases showing choroidal vascular
hyperpermeablitiy in secondary CSC, and speculated that corticosteroid might cause CSC by
unknown mechanisms that are not related to choroidal thickening. Because our study included
a great number of patients treated with steroids, we believe that CSC secondary to steroids can
occur through choroidal vascular changes such as congestion of choroidal blood flow. Zhao
et al [36]. found that intravitreal injection of the glucocorticoid corticosterone into rat eyes
induced choroidal enlargement, and suggested that the underlying mechanism is activation of
the mineralcorticoid receptor pathway by glucocorticoids, which induces upregulation of
endothelial vasodilatory potassium channel KCa2.3 (calcium-dependent channel) leading to
choroid vasodilation.
The prognosis for CSC secondary to steroids is not promising due to the severity of the
manifestations. In this study, a larger number of fluorescein leakage sites associated with a
CSC with and without steroids
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thickened choroid indicated diffuse damage of the RPE, which caused more frequent recur-
rences. Earlier recognition and discontinuation of steroids is necessary to delay visual
deterioration.
There were several limitations in this study. Because this was a retrospective study, not all
data were available. The onset of CSC was difficult to determine accurately for patients with
chronic disease, and hence the association of the duration of steroid use with the development
of CSC was not evaluated. Thus the effect of duration of steroid use on choroidal thickness
could not be analyzed. Readings of angiography and OCT were not performed at the reading
centers and there was no consensus as to treatment.
In spite of these limitations, our study illuminates the role of steroids and CSC via choroidal
vascular changes in inducing thick choroid. Further awareness of the risk of CSC due to ste-
roids is to be advised.
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